What is Tri-Mix?
Tri-Mix is a powerful treatment for erectile dysfunction that involves injecting a combination of three medications directly into the penis. It’s often used when oral medications like Viagra or Cialis don’t work or aren’t suitable. The three drugs in Tri-Mix work together to improve blood flow and help achieve an erection.

The Three Components of Tri-Mix
Papaverine
How it works: Papaverine relaxes blood vessels in the penis, allowing more blood to flow in and cause an erection. It does this by increasing certain chemical messengers (like cAMP) that help relax the smooth muscles in penile tissue.
Effectiveness: Studies show that papaverine injections can produce erections sufficient for sexual activity in most men. For example, in one study, nearly all patients achieved erections close to normal strength with biweekly injections.
Additional info: Papaverine works through multiple mechanisms, including relaxing arteries and veins in the penis, which helps trap blood and maintain the erection.
Phentolamine
How it works: Phentolamine blocks certain receptors (called alpha-adrenoceptors) that normally keep the penile muscles contracted.
Effectiveness: When combined with papaverine, phentolamine helps produce erections within 20 to 30 minutes in most patients.
Additional info: Phentolamine also affects other receptors and may increase the release of histamine, which can further help blood vessel relaxation. It has a short duration of action (about 2.5 to 4 hours) and must be injected because it’s not effective when taken by mouth.
Side effects: Rarely, it can cause low blood pressure, fast heartbeat, or heart rhythm problems.
Prostaglandin E1 (Alprostadil)
It also helps reduce blood flow out of the penis, helping maintain the erection.
Effectiveness: About 40-70% of men with ED respond well to prostaglandin E1 injections, especially when oral medications haven’t worked.
Additional info: It works mainly by increasing a chemical called cAMP, which relaxes smooth muscle. It’s quickly broken down in the body, so its effects are mostly local to the penis.
Side effects: Because it’s metabolized quickly, systemic side effects are rare, but it can cause some local discomfort.
How Tri-Mix Works Together
Each of the three drugs targets different pathways to relax penile muscles and improve blood flow. By combining them, Tri-Mix provides a stronger and more reliable erection than any single drug alone.

Administration and Use
Because it’s a potent treatment, it’s typically used under medical supervision, especially when first starting.
Dosage and frequency are carefully adjusted to balance effectiveness and minimize side effects.

Avoid this drug with hypersensitivity or allergy to any component of this formulation; conditions predispossing you to priapism; and certain drugs. (painful erection lasting 4 hours or more): sickle cell anemia, multiple myeloma or leukemia; anatomical deformity of the penis or penile implants; direction by your doctors who claim sexual activity is either unwelcome or contraindicated. Tell your doctor if you are on a medication that affects blood coagulation or have a disease.

You can take 2–4 pseudoephedrine 30 mg by mouth once and apply an ice pack if your erection lasts more than two hours. Seek expert guidance right away if your erection does not disappear in the following hour. Longer than six hours, erections have the potential to severely damage the penile tissue.

Store dry powder at 68°F to 77°F (20°C to 25°C) and away from heat, moisture and light. Once reconstituted keep this medicine in a refrigerator between 36°F to 46°F (2°C to 8°C). Keep all medicine out of the reach of children. Throw away any unused medicine after the beyond use date. Do not flush unused medications or pour down a sink or drain.

1. Montague DK, Jarow JP, Broderick GA, et al. Chapter 1: The management of erectile dysfunction: an AUA update. J Urol 2005;174:230-9.
2. Leungwattanakij S, Flynn V, Hellstrom WJG. Intracavernosal injection and intraurethral therapy for erectile dysfunction. Urol Clin North Am 2001;28:343-354.
3. Andersson, K.E., Pharmacology of penile erection. Pharmacol Rev, 2001. 53(3): p. 417-50.
4. Virag, R., et al., Vasoactive intestinal polypeptide release during penile erection in man. Lancet, 1982. 2(8308): p. 1166.
5. K.E., A., Pharmacology of erection: agents which initiate and terminate erection. Sex Disabil 1994. 12: p. 53–79.
6. Kirkeby, H.J., et al., [Infusion cavernosography and erectile dysfunction]. Ugeskr Laeger, 1990. 152(24): p. 1724-6.
7. Juenemann, K.P., et al., Hemodynamics of papaverine- and phentolamine-induced penile erection. J Urol, 1986. 136(1): p. 158-61.
8. Delcour, C., et al., The effect of papaverine on arterial and venous hemodynamics of erection. J Urol, 1987. 138(1): p. 187-9.
9. Mooradian, A.D., et al., Biweekly intracavernous administration of papaverine for erectile dysfunction. West J Med, 1989. 151(5): p. 515-7.
10. Dinsmore, W.W., Medical treatment of impotence with papaverine and phentolamine intracavernosal injection. Ulster Med J, 1990. 59(2): p. 174-6.
11. Keogh, E.J., et al., Treatment of impotence by intrapenile injections of papaverine and phenoxybenzamine: a double blind, controlled trial. Aust N Z J Med, 1989. 19(2): p. 108-12.
12. Viswaroop, B., A. B, and G. Gopalakrishnan, Evaluating erectile dysfunction: oral sildenafil versus intracavernosal injection of papaverine. Natl Med J India, 2005. 18(6): p. 299-301.
13. Traish, A.M., et al., Expression of functional alpha2-adrenergic receptor subtypes in human corpus cavernosum and in cultured trabecular smooth muscle cells. Recept Signal Transduct, 1997. 7(1): p. 55-67.
14. Traish, A., et al., Phentolamine mesylate relaxes penile corpus cavernosum tissue by adrenergic and non-adrenergic mechanisms. Int J Impot Res, 1998. 10(4): p. 215-23.
15. Wespes, E., C. Rondeux, and C.C. Schulman, Effect of phentolamine on venous return in human erection. Br J Urol, 1989. 63(1): p. 95-7.
16. P.R., I., G. B., and B.L. . Human pharmacology of orally administered phentolamine, in Phentolamine in Heart Failure and Other Cardiac Disorders., in Proceedings of an International Workshop London, November 1975 T. S.H. and G. L.A., Editors. 1975, Hans Huber Publishers: Bern, Switzerland.
17. O, H., W. U, and K. U, Systemic pharmacokinetics of papaverine and phentolamine: comparison of intravenous and intracavernous application. Int J Impot Res, 1990. 2 (Suppl 2): p. 247–248.
18. Eardley, I., et al., Pharmacotherapy for erectile dysfunction. J Sex Med, 2010. 7(1 Pt 2): p. 524-40.
19. Dinsmore, W.W. and M.G. Wyllie, Vasoactive intestinal polypeptide/phentolamine for intracavernosal injection in erectile dysfunction. BJU Int, 2008. 102(8): p. 933-7.
20. Albersen, M., et al., Evaluation and treatment of erectile dysfunction. Med Clin North Am, 2011. 95(1): p. 201-12.
21. Linet, O.I. and F.G. Ogrinc, Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl J Med, 1996. 334(14): p. 873-7.
22. Porst, H., The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol, 1996. 155(3): p. 802-15.
23. Angulo, J., et al., Rationale for the combination of PGE(1) and S-nitroso-glutathione to induce relaxation of human penile smooth muscle. J Pharmacol Exp Ther, 2000. 295(2): p. 586-93.
24. Molderings, G.J., et al., Inhibition of noradrenaline release from the sympathetic nerves of the human saphenous vein by presynaptic histamine H3 receptors. Naunyn Schmiedebergs Arch Pharmacol, 1992. 346(1): p. 46-50.
25. Palmer, L.S., et al., Characterization of cyclic AMP accumulation in cultured human corpus cavernosum smooth muscle cells. J Urol, 1994. 152(4): p. 1308-14.
26. Golub, M., et al., Metabolism of prostaglandins A1 and E1 in man. J Clin Invest, 1975. 56(6): p. 1404-10.